FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel.
NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.
